LARIMAR THERAPEUTICS, INC. Accumulated Other Comprehensive Income
LARIMAR THERAPEUTICS, INC. (LRMR) had Accumulated Other Comprehensive Income of -$12.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-04
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$12.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $6.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $54.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $66.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$12.00K 10-Q · filed 2026-08-04 |
| 2026-03-31 | $6.00K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $54.00K 10-Q · filed 2026-08-04 |
| 2025-09-30 | $66.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | -$9.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $54.00K 10-Q · filed 2025-04-30 |
| 2024-12-31 | $148.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $358.00K 10-Q · filed 2024-10-30 |
| 2024-06-30 | -$150.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$25.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $81.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $7.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $12.00K 10-Q · filed 2023-08-10 |
| 2022-12-31 | -$31.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | -$40.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$57.00K 10-Q · filed 2022-08-11 |
| 2021-06-30 | $1.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.00K 10-K · filed 2022-03-25 |
| 2020-09-30 | -$2.00K 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$3.00K 10-Q · filed 2020-08-14 |
| 2020-03-31 | $31.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $35.00K 10-Q · filed 2020-05-07 |
| 2019-09-30 | $41.00K 10-Q · filed 2019-11-06 |
| 2019-06-30 | $30.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.00K 10-Q · filed 2019-05-09 |
| 2018-12-31 | -$33.00K 10-K · filed 2020-03-05 |
| 2018-09-30 | -$28.00K 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$6.00K 10-Q · filed 2018-08-09 |
| 2018-03-31 | -$49.00K 10-Q · filed 2018-05-10 |
| 2017-12-31 | -$58.00K 10-K · filed 2019-03-14 |
| 2017-09-30 | -$28.00K 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$41.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | -$63.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | -$80.00K 10-K · filed 2018-03-09 |
| 2016-09-30 | -$66.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | -$14.00K 10-Q · filed 2016-08-05 |
| 2016-03-31 | $1.00K 10-Q · filed 2016-05-10 |
| 2015-12-31 | -$207.00K 10-K · filed 2017-03-10 |
| 2015-09-30 | -$32.00K 10-Q · filed 2015-11-13 |
| 2015-06-30 | -$60.00K 10-Q · filed 2015-08-14 |
| 2015-03-31 | -$39.00K 10-Q · filed 2015-05-14 |
| 2014-12-31 | -$35.00K 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |